Faculty of Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Department of Pediatric Oncology, Hematology and Transplantology, Institute of Pediatrics, Poznan University of Medical Sciences, Poznan, Poland.
Pathol Oncol Res. 2022 Aug 12;28:1610445. doi: 10.3389/pore.2022.1610445. eCollection 2022.
Brentuximab vedotin is a conjugate drug used mainly in Hodgkin lymphoma, systemic and primary cutaneous anaplastic large cell lymphomas, and CD30-expressing peripheral T-cell lymphoma. We report a unique case of acute pancreatitis associated with brentuximab vedotin in a 17-year-old male patient suffering from classical Hodgkin lymphoma. Diagnosed in 2020, the patient was classified to an intermediate therapeutic group and disease's grade was IIIAE. The patient was treated with brentuximab vedotin and bendamustine in the third line. Two weeks after the drug administration, the patient developed acute epigastric pain. Laboratory and radiological findings confirmed the clinical suspicion of acute pancreatitis that was managed with opioid pain medications, meropenem, parenteral nutrition, ondansetron and omeprazole. This is the first case report of brentuximab vedotin-associated acute pancreatitis in the pediatric patient reported in the literature to the best of our knowledge.
本妥昔单抗维迪昔是一种缀合物药物，主要用于霍奇金淋巴瘤、系统性和原发性皮肤间变性大细胞淋巴瘤，以及表达 CD30 的外周 T 细胞淋巴瘤。我们报告了一例在经典霍奇金淋巴瘤患者中，与本妥昔单抗维迪昔相关的急性胰腺炎的独特病例。该患者于 2020 年确诊，被分类为中危治疗组，疾病等级为 IIIAE。该患者在三线治疗中接受了本妥昔单抗维迪昔和苯达莫司汀治疗。药物治疗两周后，患者出现急性上腹痛。实验室和影像学检查结果证实了急性胰腺炎的临床诊断，给予阿片类止痛药、美罗培南、肠外营养、昂丹司琼和奥美拉唑进行治疗。据我们所知，这是迄今为止文献中首例报道的儿童患者使用本妥昔单抗维迪昔引起的急性胰腺炎病例。
